Coriell Welcomes Xiaoxin Luke Chen, MD, PhD, to its Research Team


We are pleased to announce that Xiaoxin Luke Chen, MD, PhD, has joined Coriell as a Professor and will lead a team of scientists investigating cancer. Dr. Chen brings a wealth of experience and expertise in the field of oro-esophageal cancers, or cancers found in the mouth and esophagus.

“I am delighted to welcome Dr. Chen and his team to the Coriell Institute,” said Jean-Pierre Issa, MD, Coriell’s President and Chief Executive Officer. “We are building a team of leading scientists interested in the fundamental ways our genetics and epigenetics affect our risk for developing cancer and how that knowledge can be used to develop new treatments. Dr. Chen and his lab are a perfect fit.”

Recent work from Dr. Chen’s lab has focused on metabolism and cell signaling with regard to esophageal squamous cell carcinoma, a type of cancer that forms in the lining of the esophagus. His team has published numerous papers in leading journals, including the Journal of Pathology, Nature, and Cell Stem Cell.

“I am excited by the opportunity to continue my work at Coriell,” Dr. Chen said. “I look forward to joining the Institute and to exploring potential collaborations between myself and the talented scientists already conducting great work at Coriell. There are many areas of shared interests and synergies that make this ideal.”

Dr. Chen is a shared employee between Coriell Institute for Medical Research and Cooper University Health Care and his team is spread across both organizations.

Prior to joining Coriell as Professor, Dr. Chen served as a tenured Professor of Biological and Biomedical Sciences at The Julius L. Chambers Biomedical and Biotechnology Research Institute, North Carolina Central University. He was named Glaxo Distinguished Professor of Biomedical Science in 2020.

Dr. Chen received his Doctor of Philosophy in Biochemistry from Rutgers University-New Brunswick and a Bachelor of Medicine from Peking University Health Sciences Center in Beijing, China. His postdoctoral training was completed at Rutgers University-New Brunswick in the College of Pharmacy.

About the Coriell Institute for Medical Research

Founded in 1953, the Coriell Institute for Medical Research is a nonprofit research institute dedicated to improving human health through biomedical research. Coriell scientists lead research in personalized medicine, cancer biology, epigenetics, and the genomics of opioid use disorder. Coriell also hosts one of the world's leading biobanks—comprised of collections for the National Institutes of Health, disease foundations and private clients—and distributes biological samples and offers research and biobanking services to scientists around the globe. To facilitate drug discovery and disease study, the Institute also develops and distributes collections of induced pluripotent stem cells. For more information, visit

Other News